Clinical outcomes in Gastric Adenocarcinoma and Proximal Polyposis of the Stomach (GAPPS). Led by University of British Columbia in Vancouver, Canada. Project participants from RGIC are Dr Astrid Stormorken and Dr Kristine Lillestøl.
GENEPAC (GENetic risk factors for PAncreatic Cancer). Collaboration with the Cancer Registry of Norway, Institute of Cancer Research, UK and National Cancer Institute, USA. Principal Investigator is Eli Marie Grindedal.
IMPACT (Identification of Men With a Genetic Predisposition to ProstAte Cancer). Led by Professor Ros Eeles at Institute of Cancer Research UK. Project members from RGIC are Lovise Mæhle and Eli Marie Grindedal. Our research group is currently working on a study on risk of prostate cancer in men with germline mutations in one of the four MMR-genes.
PRACTICAL (Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome). Led by Professor Ros Eeles at Institute of Cancer Research UK. Project member from RGIC are Lovise Mæhle and Eli Marie Grindedal.
GENPROS (Analysing outcomes after prostate cancer diagnosis and treatment in carriers of rare germline mutations in cancer predisposition genes). Led by Professor Ros Eeles at Institute of Cancer Research UK. Project members from RGIC are Lovise Mæhle and Eli Marie Grindedal
TUBA-WISPII (TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention).The study is led by the Uniiversity Medical Center Nijmegen and MD Anderson. The PI at Oslo University Hospital is Dr Anne Dørum at Section of Gyneacological Cancer. Project members from RGIC are Tone Vamre and Nora Martinussen Tandstad.
INSPECT (INveStigation into PTEN-related Cancer and phenoType). Led by Radoudumc in the Netherlands. Project member from RGIC is Kjersti Jørgensen.
National research projects
KNEP (Norwegian Cancer Society – National Group of Expertise for Research on Pancreatic Cancer). Led by Professor Caroline Verbeke from Oslo University Hospital and University of Oslo. Eli Marie Grindedal is the leader for the work package on medical genetics. An ongoing project is to investigate risk of pancreatic cancer in carriers of pathogenic variants in BRCA1 or BRCA2.
PREPAIRD-study (Personalized Surveillance for Early Detection and Prevention of Pancreatic Cancer in High-Risk Individuals). This is a national project to establish and evaluate a surveillance program for early detection and prevention of pancreatic cancer in individuals with a hereditary predisposition to the disease. Surveillance consists of a combination of annual imaging and evaluation of blood borne biomarkers. Project leader is Eli Marie Grindedal from RGIC
FARVERIK-study (Prevention of Hereditary Cancer in Women). PhD-project for Hanne Kjensli Hyldebrandt. The project includes two cohorts of women: Women with inherited mutations in one of the MMR-genes (Lynch Syndrome), and women with inherited mutations in one of the two breast cancer genes BRCA1 and BRCA2. We will investigate cancer risk, uptake of preventive surgery, consequences and experiences of preventive surgery in these cohorts. Main supervisor is Astrid Stormorken from RGIC.
INTERPRET-study (Patients’ Experiences with Panel Testing for Hereditary Cancer). This is a quality of care study where we will investigate how patients at Section of Inherited Cancer, who receive genetic counseling and genetic testing of a gene panel for hereditary cancer, experience this health care service. Project leaders are Sigrid Tronsli Hovland and Eli Marie Grindedal.
Genetic causes of bladder cancer. Collaboration with Department of Urology at Akershus University Hospital.
Autophagy and cancer development in patients with mutations in FLCN. Project leader is Helene Knævelsrud at Institute of Cancer Research at Oslo University Hospital. Project member from RGIC is Kjersti Jørgensen.
Study on late effects after prophylactic removal of ovaries (https://brca.no). This study is led by Dr Nora Johansen at Sørlandet Sykehus, Arendal. Project members from RGIC are Tone Vamre and Eli Marie Grindedal. The aim of the project is to investigate whether prophylactic removal of ovaries in women with inherited mutations in BRCA1 or BRCA2 affects their health in the long term.
Huynh-Le MP, Karunamuni R, Fan CC, Asona L, Thompson WK, Martinez ME, Eeles RA, Kote-Jarai Z, Muir KR, Lophatananon A, Schleutker J, Pashayan N, Batra J, Grönberg H, Neal DE, Nordestgaard BG, Tangen CM, MacInnis RJ, Wolk A, Albanes D, Haiman CA, Travis RC, Blot WJ, Stanford JL, Mucci LAet al.(2022) Prostate cancer risk stratification improvement across multiple ancestries with new polygenic hazard score Prostate Cancer Prostatic Dis(in press) DOI 10.1038/s41391-022-00497-7, PubMed 35152271
Strømsvik N, Olsson P, Gravdehaug B, Lurås H, Schlichting E, Jørgensen K, Wangensteen T, Vamre T, Heramb C, Mæhle L, Grindedal EM(2022) "It was an important part of my treatment": a qualitative study of Norwegian breast Cancer patients' experiences with mainstreamed genetic testing Hered Cancer Clin Pract, 20(1), 6 DOI 10.1186/s13053-022-00212-6, PubMed 35123550
Bancroft EK, Page EC, Brook MN, Thomas S, Taylor N, Pope J, McHugh J, Jones AB, Karlsson Q, Merson S, Ong KR, Hoffman J, Huber C, Maehle L, Grindedal EM, Stormorken A, Evans DG, Rothwell J, Lalloo F, Brady AF, Bartlett M, Snape K, Hanson H, James P, McKinley Jet al.(2021) A prospective prostate cancer screening programme for men with pathogenic variants in mismatch repair genes (IMPACT): initial results from an international prospective study Lancet Oncol, 22(11), 1618-1631 DOI 10.1016/S1470-2045(21)00522-2, PubMed 34678156
Get in touch
Contact information Eli Marie Grindedal, Department of Medical Genetics Tel: + (47) 99 31 71 81/23 07 55 41, E-mail: ELIGR@ous-hf.no